Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Immunol ; 212(1): 154-164, 2024 01 01.
Article in English | MEDLINE | ID: mdl-37966267

ABSTRACT

The proteasome inhibitor bortezomib (BTZ) is proposed to deplete activated B cells and plasma cells. However, a complete picture of the mechanisms underlying BTZ-induced apoptosis in B lineage cells remains to be established. In this study, using a direct in vitro approach, we show that deletion of the tumor suppressor and cell cycle regulator p53 rescues recently activated mouse B cells from BTZ-induced apoptosis. Furthermore, BTZ treatment elevated intracellular p53 levels, and p53 deletion constrained apoptosis, as recently stimulated cells first transitioned from the G1 to S phase of the cell cycle. Moreover, combined inhibition of the p53-associated cell cycle regulators and E3 ligases MDM2 and anaphase-promoting complex/cyclosome induced cell death in postdivision B cells. Our results reveal that efficient cell cycle progression of activated B cells requires proteasome-driven inhibition of p53. Consequently, BTZ-mediated interference of proteostasis unleashes a p53-dependent cell cycle-associated death mechanism in recently activated B cells.


Subject(s)
Antineoplastic Agents , Proteasome Inhibitors , Animals , Mice , Bortezomib/pharmacology , Bortezomib/metabolism , Proteasome Inhibitors/pharmacology , Antineoplastic Agents/pharmacology , Tumor Suppressor Protein p53/metabolism , Cell Line, Tumor , Proteasome Endopeptidase Complex/metabolism , Apoptosis
SELECTION OF CITATIONS
SEARCH DETAIL